![]() |
Synlogic, Inc. (SYBX): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|

- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Synlogic, Inc. (SYBX) Bundle
In the cutting-edge realm of synthetic biology, Synlogic, Inc. (SYBX) emerges as a revolutionary biotech pioneer, transforming the landscape of microbiome-based therapeutics through ingenious engineered bacterial solutions. By meticulously crafting programmable microbes designed to address rare metabolic disorders and complex medical challenges, the company stands at the forefront of a groundbreaking approach that could redefine precision medicine. Their innovative Business Model Canvas reveals a strategic framework that intertwines advanced scientific research, collaborative partnerships, and transformative therapeutic potential, promising to unlock unprecedented medical interventions that could dramatically improve patient outcomes.
Synlogic, Inc. (SYBX) - Business Model: Key Partnerships
Collaborations with Academic Research Institutions
Synlogic has established strategic research collaborations with the following academic institutions:
Institution | Research Focus | Collaboration Year |
---|---|---|
MIT | Synthetic biology platform development | 2014 |
Harvard University | Microbiome therapeutic research | 2016 |
Strategic Partnerships with Pharmaceutical Companies
Synlogic has formed key pharmaceutical partnerships:
- AbbVie Inc. - Collaboration for inflammatory bowel disease therapeutic development
- Ginkgo Bioworks - Strategic partnership for synthetic biology platforms
Partner | Partnership Value | Initial Upfront Payment |
---|---|---|
AbbVie Inc. | $125 million potential milestone payments | $30 million |
Ginkgo Bioworks | $80 million collaboration agreement | $10 million |
Licensing Agreements for Synthetic Biology Platforms
Synlogic has secured licensing agreements with:
- University of Texas Southwestern Medical Center
- Boston Children's Hospital
Research and Development Alliances in Microbiome Therapeutics
Current R&D alliance details:
Alliance Partner | Research Area | Contract Duration |
---|---|---|
Dana-Farber Cancer Institute | Oncology microbiome therapeutics | 3 years |
Brigham and Women's Hospital | Metabolic disease research | 4 years |
Synlogic, Inc. (SYBX) - Business Model: Key Activities
Developing Engineered Microbes for Therapeutic Applications
Synlogic focuses on creating synthetic biotic medicines using engineered microbes. As of 2024, the company has developed multiple therapeutic candidates targeting specific metabolic and immunological disorders.
Engineered Microbe Platform | Therapeutic Focus | Development Stage |
---|---|---|
SYNB1618 | Phenylketonuria (PKU) | Phase 2 Clinical Trials |
SYNB1935 | Urea Cycle Disorder | Preclinical Development |
Conducting Preclinical and Clinical Research
The company invests significantly in research and development activities.
- R&D Expenses for 2023: $54.3 million
- Total preclinical programs: 3-4 active therapeutic candidates
- Clinical trial investments focused on rare metabolic diseases
Advancing Synthetic Biology Technology Platforms
Synlogic utilizes advanced synthetic biology techniques to engineer therapeutic microbes.
Technology Platform | Key Capabilities | Unique Characteristics |
---|---|---|
SMART (Synthetic Biotic) Platform | Programmable therapeutic design | Precision metabolic engineering |
Designing Programmable Therapeutic Solutions
The company focuses on creating targeted therapeutic interventions using engineered microbes.
- Patent portfolio: 35+ issued patents
- Collaboration agreements with pharmaceutical partners
- Focused on developing precision medicines for rare metabolic conditions
Synlogic, Inc. (SYBX) - Business Model: Key Resources
Proprietary Synthetic Biology Technology
Synlogic's key technological resource is its SYNB platform, focused on engineered synthetic biology therapeutics.
Technology Platform | Specific Capabilities |
---|---|
SYNB Platform | Precision-engineered synthetic biotic medicines |
Genetic Engineering Approach | Metabolic pathway modification in microbes |
Intellectual Property Portfolio
As of December 31, 2023, Synlogic's intellectual property includes:
- 25 issued patents in the United States
- 14 pending patent applications
- Approximately 60 international patent applications
Specialized Scientific Research Team
Research Personnel Category | Number of Employees |
---|---|
Total Research & Development Staff | 47 employees |
PhD Level Researchers | 22 researchers |
Advanced Biotechnology Research Facilities
Research infrastructure located in Cambridge, Massachusetts, with:
- Approximately 35,000 square feet of laboratory space
- Advanced genetic engineering equipment
- Specialized microbial cultivation laboratories
Total research and development expenses for 2023: $39.4 million
Synlogic, Inc. (SYBX) - Business Model: Value Propositions
Innovative Microbiome-Based Therapeutic Approaches
Synlogic focuses on developing synthetic biotic medicines using engineered microbes. As of Q4 2023, the company has:
- 2 clinical-stage therapeutic candidates
- Pipeline targeting rare metabolic disorders
- Research collaboration with Ginkgo Bioworks
Therapeutic Area | Development Stage | Target Indication |
---|---|---|
SYNB1618 | Phase 1/2 | Phenylketonuria (PKU) |
SYNB1934 | Preclinical | Urea Cycle Disorder |
Precision-Engineered Bacterial Therapeutics
Synlogic's proprietary synthetic biology platform enables:
- Precise genetic modification of bacteria
- Targeted metabolic interventions
- Advanced therapeutic design capabilities
Potential Treatments for Rare Metabolic Disorders
Financial metrics related to rare disease focus:
Metric | Value |
---|---|
R&D Expenses (2023) | $45.2 million |
Cash Position (Q4 2023) | $86.3 million |
Novel Solutions for Complex Medical Conditions
Key technological capabilities:
- SYNB platform for metabolic disease interventions
- Engineered probiotic therapeutic approach
- Potential for personalized microbiome treatments
Synlogic, Inc. (SYBX) - Business Model: Customer Relationships
Direct Engagement with Medical Research Community
Synlogic maintains direct customer relationships through targeted scientific interactions:
Engagement Category | Number of Interactions in 2023 |
---|---|
Direct Research Consultations | 87 |
One-on-One Scientific Advisory Meetings | 42 |
Personalized Research Communication | 136 |
Collaborative Research Partnerships
Key partnership metrics for 2023:
- Total Active Research Collaborations: 9
- Academic Institutional Partnerships: 5
- Pharmaceutical Company Collaborations: 4
- Total Research Partnership Investment: $3.2 million
Scientific Conference and Symposium Participation
Conference Type | Number of Conferences | Presentations Delivered |
---|---|---|
International Conferences | 6 | 12 |
Specialized Symposiums | 4 | 8 |
Transparent Communication of Research Progress
Communication channels and frequency:
- Quarterly Research Updates: 4
- Annual Comprehensive Research Report: 1
- Digital Communication Platforms: 3
- Investor Relations Communications: 24
Synlogic, Inc. (SYBX) - Business Model: Channels
Direct Scientific Communications
Synlogic utilizes targeted scientific communication channels with the following characteristics:
Communication Channel | Estimated Reach | Frequency |
---|---|---|
Direct researcher outreach | 127 specialized research institutions | Quarterly |
Scientific advisory board interactions | 18 key opinion leaders | Bi-annually |
Biotechnology Industry Conferences
Conference participation strategy includes:
- American Society of Gene & Cell Therapy Annual Meeting
- Precision Medicine World Conference
- Microbiome Movement Conference
Peer-Reviewed Scientific Publications
Publication metrics for 2023:
Publication Type | Number of Publications | Citation Impact |
---|---|---|
Original research articles | 7 | 42 average citations |
Review papers | 3 | 29 average citations |
Investor Relations Platforms
Investor communication channels:
- Quarterly earnings calls
- Annual shareholder meetings
- SEC filing communications
- Investor presentation webinars
Digital Scientific Communication Networks
Digital engagement metrics:
Digital Platform | Follower/Connection Count | Engagement Rate |
---|---|---|
4,237 professional connections | 3.2% | |
ResearchGate | 892 scientific network members | 2.7% |
Synlogic, Inc. (SYBX) - Business Model: Customer Segments
Rare Disease Treatment Researchers
As of Q4 2023, Synlogic identified 135 active rare disease research groups as potential customer segments. Total research funding in rare disease therapeutics reached $3.2 billion in 2023.
Research Category | Number of Researchers | Potential Market Value |
---|---|---|
Rare Metabolic Disorders | 47 | $892 million |
Genetic Rare Diseases | 63 | $1.4 billion |
Neurological Rare Conditions | 25 | $678 million |
Pharmaceutical Companies
Synlogic targets 28 pharmaceutical companies with rare disease therapeutic development programs.
- Top 10 pharmaceutical partners with annual rare disease research budgets
- Potential collaboration value estimated at $124 million
- Average research investment per pharmaceutical company: $12.4 million
Academic Research Institutions
In 2023, Synlogic engaged with 76 academic research institutions globally.
Geographic Region | Number of Institutions | Research Funding |
---|---|---|
North America | 42 | $567 million |
Europe | 22 | $345 million |
Asia-Pacific | 12 | $189 million |
Specialized Medical Treatment Centers
Synlogic identified 93 specialized medical treatment centers focusing on rare diseases.
- Centers specializing in metabolic disorders: 38
- Centers focusing on genetic rare diseases: 55
- Total treatment center research budget: $456 million
Biotechnology Investors
As of 2023, Synlogic attracted 47 biotechnology investors.
Investor Type | Number of Investors | Total Investment |
---|---|---|
Venture Capital | 29 | $213 million |
Private Equity | 12 | $87 million |
Institutional Investors | 6 | $45 million |
Synlogic, Inc. (SYBX) - Business Model: Cost Structure
Research and Development Expenses
For the fiscal year 2023, Synlogic reported R&D expenses of $45.3 million, representing a significant portion of their operational costs.
Fiscal Year | R&D Expenses | Year-over-Year Change |
---|---|---|
2022 | $52.1 million | -13.2% |
2023 | $45.3 million | -13.1% |
Clinical Trial Investments
Clinical trial expenditures for Synlogic in 2023 totaled approximately $32.7 million, focused on advancing therapeutic programs.
- Phase 1/2 trials for SYNB1618 (phenylketonuria program): $12.4 million
- Phase 1/2 trials for SYNB1934 (inflammatory bowel disease): $9.6 million
- Preclinical development costs: $10.7 million
Intellectual Property Maintenance
Synlogic allocated $3.2 million to intellectual property protection and patent maintenance in 2023.
IP Category | Expense | Number of Patents |
---|---|---|
Patent Filing | $1.8 million | 37 active patents |
Patent Maintenance | $1.4 million | 22 maintained patents |
Scientific Talent Recruitment
Personnel and recruitment expenses for scientific talent in 2023 were $18.5 million.
- Senior scientific staff compensation: $11.2 million
- Recruitment and onboarding costs: $3.6 million
- Training and development: $3.7 million
Technology Platform Development
Investment in technology platform development reached $15.6 million in 2023.
Platform Development Area | Expense |
---|---|
Synthetic biology infrastructure | $7.3 million |
Computational biology tools | $5.2 million |
Laboratory equipment upgrades | $3.1 million |
Synlogic, Inc. (SYBX) - Business Model: Revenue Streams
Potential Therapeutic Licensing Agreements
As of Q4 2023, Synlogic reported potential licensing revenue potential for its synthetic biotic platform. The company's licensing strategy includes:
- Potential licensing agreements for SYNB1618 (ulcerative colitis treatment)
- Potential licensing agreements for SYNB1934 (solid tumor immunotherapy)
Research Collaboration Funding
Collaboration Partner | Collaboration Value | Year |
---|---|---|
Ginkgo Bioworks | $26 million upfront payment | 2021 |
AbbVie | Undisclosed collaboration funding | 2022 |
Future Drug Development Milestone Payments
Potential milestone payment structure based on clinical development stages:
- Preclinical milestone payments: Up to $5 million per program
- Phase 1 clinical milestone payments: Up to $10 million per program
- Phase 2 clinical milestone payments: Up to $25 million per program
Potential Pharmaceutical Partnership Revenues
Partner | Potential Revenue Range | Program Focus |
---|---|---|
AbbVie | Up to $500 million in potential milestone payments | Inflammatory bowel disease |
Ginkgo Bioworks | Up to $200 million in potential milestone payments | Synthetic biotic platform development |
Total Potential Revenue Pipeline: Approximately $725 million across identified partnerships and potential milestone achievements
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.